References
1. Le Loarer F, Watson S, Pierron G, et al. SMARCA4 inactivation defines
a group of undifferentiated thoracic malignancies transcriptionally
related to BAF-deficient sarcomas. Nat Genet .
2015;47(10):1200-1205. doi:10.1038/ng.3399.
2. Rekhtman N, Montecalvo J, Chang JC, et al. SMARCA4-deficient thoracic
sarcomatoid tumors represent primarily smoking-related undifferentiated
carcinomas rather than primary thoracic sarcomas. J Thorac Oncol .
2020;15(2):231-247. doi:10.1016/j.jtho.2019.10.023.
3. Henon C, Blay JY, Massard C, et al. Long lasting major response to
pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient
tumor. Ann Oncol . 2019;30(8):1401-1403. doi:10.1093/annonc/mdz160.
4. Takada K, Sugita S, Murase K, et al. Exceptionally rapid response to
pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing
PD-L1: A case report. Thorac Cancer . 2019;10(12):2312-2315. doi:10.1111/1759-7714.13215.
5. Naito T, Umemura S, Nakamura H, et al. Successful treatment with
nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a
high tumor mutation burden: A case report. Thorac Cancer .
2019;10(5):1285-1288. doi:10.1111/1759-7714.13070.
6. Iijima Y, Sakakibara R, Ishizuka M, et al. Notable response to
nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: A
case report. Immunotherapy . 2020;12(8):563-569. doi:10.2217/imt-2019-0142.
7. Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus
ipilimumab in advanced non–small-cell lung cancer. N Engl J Med .
2019;381(21):2020-2031. doi:10.1056/NEJMoa1910231.
8. Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation
criteria in solid tumours: Revised RECIST guideline (version 1.1).Eur J Cancer . version 1.1. 2009 January;45(2):228-247. doi:10.1016/j.ejca.2008.10.026.
9. Hu J-R, Florido R, Lipson EJ, et al. Cardiovascular toxicities
associated with immune checkpoint inhibitors. Cardiovasc Res .
2019 April 15;115(5):854-868. doi:10.1093/cvr/cvz026.
10. Tanaka S, Hayashi S, Isobe Y, et al. Positive outcome of first-line
therapy for a SMARCA4-deficient thoracic sarcomatoid tumor. Int
Cancer Conf J . 2021;10(2):112-115. doi:10.1007/s13691-021-00472-4.
11. Kawachi H, Kunimasa K, Kukita Y, et al. Atezolizumab with
bevacizumab, paclitaxel, and carboplatin was effective for patients with
SMARCA4-deficient thoracic sarcoma. Immunotherapy .
2021;13(10):799-806. doi:10.2217/imt-2020-0311.
12. AnŽič N, Krasniqi F, Eberhardt AL, Tzankov A, Haslbauer JD.
Ipilimumab and pembrolizumab mixed response in a 41-year-old patient
with SMARCA4-deficient thoracic sarcoma: An interdisciplinary case
study, Case. Case Rep Oncol . 2021;14(2):706-715. doi:10.1159/000515416.
13. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus
Chemotherapy for PD-L1–Positive non–small-Cell Lung Cancer. N
Engl J Med . 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774.
14. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for
first-line treatment of PD-L1–selected patients with NSCLC. N
Engl J Med . 2020;383(14):1328-1339. doi:10.1056/NEJMoa1917346.
15. Middleton G, Brock K, Savage J, et al. Pembrolizumab in patients
with non-small-cell lung cancer of performance status 2 (PePS2): A
single arm, phase 2 trial. Lancet Respir Med . 2020;8(9):895-904.
doi:10.1016/S2213-2600(20)30033-3.